Eva Fechter

Suggest Changes
Learn More
4588 Background: Everolimus is a potent, orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) pathway and has shown activity in preclinical cancer models. This phase II study(More)
  • 1